Diagnostic Utility of a Cost-Effective Four-Gene Next Generation Sequencing Panel for Predicting Papillary Thyroid Carcinoma in Indeterminate Thyroid Cytology: A Multicenter Study in China.

In this cross-sectional study, we evaluated the diagnostic utility of a targeted next-generation sequencing (next-generation sequencing) 4-gene panel, including BRAF V600E , TERT promoter mutations, RET fusions, and NTRK3 fusion, for enhancing the cytological diagnosis of thyroid nodules prior to surgical intervention.

The observed prevalence of molecular alterations was: BRAF V600E , 68.3% (526/770); TERT promoter mutations, 10.3% (79/770); RET fusions, 10.3% (79/770); and NTRK3 fusion, 3.9% (30/770).